摘要
目的评价不同剂量阿托伐他汀对血脂正常冠心病患者的疗效。方法根据阿托伐他汀剂量不同,将收治的血脂正常冠心病患者378例分为10 mg组、20 mg组和40 mg组,每组126例。比较3组治疗前后炎性反应指标、心功能指标、颈动脉斑块面积、内膜中层厚度、心血管事件及不良反应等。结果3组患者治疗后炎性指标、LDL-C、心功能指标、颈动脉斑块面积、内膜中层厚度组间差异均有统计学意义(P<0.05),治疗后3组炎性指标及LDL-C较治疗前均明显下降(P<0.05)、心功能指标较治疗前明显改善(P<0.05)、颈动脉斑块指标较治疗前明显缩小(P<0.05),其中40 mg组改变最明显(P<0.05)。40 mg组治疗后的心血管事件发生率最少(P<0.05),3组间不良反应发生率差异无统计学意义(P>0.05)。结论较大剂量的阿托伐他汀对血脂正常的冠心病患者安全、有效。
Objective To investigate the therapeutic effects of different doses of atorvastatin on coronary heart disease(CHD)in patients with normal lipid levels.Methods According to the different doses of atorvastatin,the 378 CHD patients with normal blood lipid levels were divided into low-dose(10mg)group,medin-dose(20mg)group and high-dose(40mg)group,with 126 cases in each group.The changes of inflammatory response indexes,LDL-C,cardiac function indexes,carotid plaque area,intima-media thickness,cardiovascular events and adverse reactions before and after treatment were observed and compared among the three groups.Results After treatment there were significant differences in the inflammation indexes,LDL-C,cardiac function indexes,carotid plaque area and intima-media thickness among the three groups(P<0.05).After treatment,the inflammation indexes and LDL-C levels in the three groups were significantly decreased(P<0.05),and cardiac function indexes were significantly improved(P<0.05).Moreover the carotid plaque indexed were significantly decreased,in which,the change were most obvious in high-dose group(P<0.05),and the incidence rate of cardiovascular events was the lowest in high-dose group(P<0.05).However there were no significant differences in the incidence rates of adverse reactions among the three groups(P>0.05).Conclusion The high-dose atorvastatin is safe and effective in treatment of CHD in patients with normal blood lipid levels.
作者
刘阳
LIU Yang(Department of General Practice,Guangwai Community Health Service Center,Xicheng District,Beijing 100055,China)
出处
《河北医药》
CAS
2021年第1期94-97,共4页
Hebei Medical Journal
关键词
阿托伐他汀
血脂
冠心病
剂量
治疗结果
atorvastatin
blood lipid
coronary heart disease
dose
treatment outcome